Search results
Results from the WOW.Com Content Network
Screening for prostate cancer begins with a test that measures the amount of prostate-specific antigen (PSA) protein in the blood. An elevated PSA level may be caused by prostate cancer but can also be caused by other conditions, including an enlarged prostate (benign prostatic hyperplasia) and inflammation of the prostate (prostatitis).
Prostate Cancer: Screening. An Update for This Topic is In Progress. LAST UPDATED: Dec 21, 2023. The Task Force keeps recommendations as current as possible by routinely updating existing recommendations and developing new recommendations. A multistep process is followed for each recommendation.
Based on a review of the evidence, the Task Force recommends that men aged 55 to 69 years make an individual decision about whether to be screened after a conversation with their clinician about the potential benefits and harms.
The USPSTF recommends against PSA-based screening for prostate cancer in men 70 years and older. D recommendation. See the Clinical Considerations section for more information on screening...
In 2018, the US Preventive Services Task Force (USPSTF) made the following recommendations about prostate cancer screening: Men who are 55 to 69 years old should make individual decisions about being screened for prostate cancer with a prostate specific antigen (PSA) test.
The USPSTF concludes with moderate certainty that the net benefit of PSA-based screening for prostate cancer in men aged 55 to 69 years is small for some men. How each man weighs specific benefits and harms will determine whether the overall net benefit is small.
The U.S. Preventive Services Task Force (USPSTF) recommends that men ages 55 to 69 years discuss the possible benefits and harms of prostate-specific antigen (PSA) screening with their health care provider and make an individualized decision about whether to get screened.
After this discussion, men who want to be screened should get the prostate-specific antigen (PSA) blood test. The digital rectal exam (DRE) may also be done as a part of screening. (See Screening Tests for Prostate Cancer.)
This topic reviews the efficacy of screening and recommendations regarding screening for prostate cancer. Risk factors, clinical manifestations, and diagnosis of prostate cancer are discussed separately.
The USPSTF, alternatively, recommends these prostate cancer screening guidelines: Men ages 55 to 69: Men should discuss a prostate-specific antigen (PSA) screening with their doctor to make an informed decision. Men 70 and older: PSA-based screening isn’t recommended.